Evofem Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $391 | $(8,860) |
| Adjustments to reconcile net income (loss) to net restricted cash and cash equivalents used in operating activities: | ||
| Loss on issuance of financial instruments | - | 3,300 |
| Gain on debt extinguishment | - | (977) |
| Gain on change in accounting estimates on contingent royalty liability | (1,933) | - |
| Change in fair value of financial instruments | 359 | (3,698) |
| Inventory write-down for excess & obsolescence and loss on purchase commitment | 1,012 | 63 |
| Loss on contingent liability | 54 | 840 |
| Stock-based compensation | 166 | 847 |
| Depreciation | 19 | 30 |
| Amortization of intangible asset | 499 | 619 |
| Noncash interest expense | 2,366 | 2,243 |
| Noncash right-of-use asset amortization | 108 | 107 |
| Net loss on disposal or impairment of property and equipment | 20 | 734 |
| Gain on accounts payable and accrued expenses settlements | (5,636) | - |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | (2,648) | (4,094) |
| Inventories | (260) | 57 |
| Prepaid and other assets | 356 | (265) |
| Accounts payable | 182 | (910) |
| Accrued expenses and other liabilities | 4,468 | 5,300 |
| Accrued compensation | (907) | 885 |
| Contingent liabilities | (499) | - |
| Operating lease liabilities | (109) | (106) |
| Net restricted cash and cash equivalents used in operating activities | (1,992) | (3,885) |
| Cash flows from investing activities: | ||
| Payments related to intangible asset acquisition | (57) | (555) |
| Purchases of property and equipment | (5) | (14) |
| Net restricted cash and cash equivalents used in investing activities | (62) | (569) |
| Cash flows from financing activities: | ||
| Borrowings under short-term debt | 383 | 397 |
| Proceeds from issuance of Aditxt Notes – Related Party | 2,425 | - |
| Proceeds from issuance of Series F-1 Shares to Aditxt, including reinstatement proceeds - Related Party | - | 5,000 |
| Payments under short-term debt and Notes – carried at fair value | (905) | (782) |
| Cash paid for financing costs | (12) | - |
| Net restricted cash and cash equivalents provided by financing activities | 1,891 | 4,615 |
| Net change in restricted cash and cash equivalents | (163) | 161 |
| Restricted cash and cash equivalents, beginning of period | 741 | 580 |
| Restricted cash and cash equivalents, end of period | $578 | $741 |
| Supplemental cash flow information: | ||
| Cash paid for interest | 16 | 159 |
| Cash paid for taxes | 2 | 8 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Net increase/(decrease) in contingent liabilities | (4,751) | 13,743 |
| Exchange of convertible notes to Series G-1 convertible and redeemable preferred stock | 381 | - |
| Series E-1 and G-1 Shares deemed dividends | 117 | 105 |
| Addition to ROU asset and lease liability due to new leases | 201 | 90 |
| Purchases of property and equipment included in accounts payable and accrued expenses | 78 | 84 |
| Issuance of Common Stock upon exercise of purchase rights | 4 | 169 |
| Issuance of Common Stock upon conversion of notes | - | 52 |
| Issuance of Common Stock upon exercise of warrants | - | 15 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.